Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2019-05-09 Interim / Quarterly Rep…
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
10-Q Filing
Interim / Quarterly Report Q1 2019
2019-05-09 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 9, 2019, by Aerpio Pharmaceuticals, Inc. It announces the company's financial results for the quarter ended March 31, 2019, and includes a press release as an exhibit. The text explicitly states it is a current report pursuant to the Securities Exchange Act of 1934, and the content is a brief announcement of quarterly financial results rather than a full detailed report. The document length is 3331 characters, which is relatively short and consistent with an earnings release rather than a comprehensive interim report. Therefore, this filing is best classified as an Earnings Release (ER).
2019-05-09 English
DEF 14A Filing
Proxy Solicitation & Information Statement
2019-04-30 English
SC 13D/A Filing
Major Shareholding Notification
2019-04-29 English
SC 13D/A Filing
Major Shareholding Notification
2019-04-11 English
8-K Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 10, 2019. It specifically mentions furnishing a corporate presentation attached as Exhibit 99.1, which the company intends to use in meetings with investors. The text states that the presentation is not filed for purposes of Section 18 and is intended for investor relations use. The document length is 3240 characters, which is relatively short and primarily serves as an announcement of the presentation rather than the presentation itself. According to the MENU VS MEAL RULE, this is an announcement of a report (the investor presentation) rather than the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2019-04-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.